Tebamide Pediatric Disease Interactions

The use of trimethobenzamide should be avoided in children and adolescents whose signs and symptoms suggest Reye's syndrome. The extrapyramidal symptoms which can occur secondary to trimethobenzamide use may confound the diagnosis of Reye's syndrome. In addition, drugs with hepatotoxic potential such as trimethobenzamide may adversely affect the course of Reye's syndrome.

Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis. Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia. If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.

The use of trimethobenzamide has been associated with pseudo- parkinsonian reactions including mask- like faces, drooling, cogwheel rigidity, and shuffling gait. Therapy with trimethobenzamide should be administered cautiously in patients with parkinsonism.

Trimethobenzamide is mostly eliminated by the kidneys and a dosage adjustment should be considered in patients with reduced renal function (creatinine clearance <= 70 mL/min), including some elderly patients.